Lilly Ventures and Amgen Ventures have co-led protein degradation-based biotech startup Kymera's series A round with Atlas Venture.
Kymera Therapeutics, a US-based developer of drugs for hitherto untreatable diseases, raised $30m yesterday in a series A round co-led by the corporate venturing subsidiaries of pharmaceutical firms Amgen and Eli Lilly.
Lilly Ventures and Amgen Ventures were joined in the round by Atlas Venture, the venture capital firm that incubated Kymera. Atlas Venture also provided the startup’s seed funding, though details of its investment have not been revealed.
Kymera is using predictive modelling developing therapies that will combat diseases…
